A National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19

drug protocol number
20-COVID-19-01M
drug sponsor
GDRS (MOH)
drug study
Convalescent Plasma
drug trial site
KFSH-D
drug status
Ongoing
drug phase